AIMEDIC announced on the 17th that it has signed a supply contract with Taiwan's Chilli Enterprise granting it the right to sell its artificial intelligence (AI) medical devices, 'HeartMedi+' and 'AutoSeg', in Taiwan.
This contract was made after HeartMedi+ was recently designated as an innovative medical device as it began domestic clinical applications, and AImedic explained that this was a result of its recognition in the Taiwanese medical device market, thereby establishing a foundation for overseas supply.
HeartMedi+ is an AI-based cardiovascular diagnostic assistance software that utilizes CT-FFR technology to evaluate coronary artery stenosis and noninvasively quantify cardiovascular risk to help medical professionals make precise diagnoses. AutoSeg is an AI-based coronary artery and heart automatic analysis software that identifies anatomical information about the coronary artery, aorta, and heart in cardiac CT images and provides various lesion analysis results.
Under the agreement, Chili Enterprises will be responsible for licensing (TFDA), marketing and public relations in Taiwan, and the two companies will work together to conduct business in the Taiwanese market.
- See more related articles
You must be logged in to post a comment.